Introduction
Hypersensitivity to antiepileptic drugs (AEDs) can occur as an idiosyncratic reaction. It is unpredictable and not dose related. Several different hypersensitivity reactions have been reported with AEDs. The most common type of adverse reaction is mild skin rash. 1 More serious reactions can also occur as toxic epidermal necrolysis, Stevens-Johnson syndrome or Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Another uncommon acute life threatening allergic reaction is angioedema. Many drug hypersensitivity reactions result from reactive drug metabolites and reflect either a direct cytotoxic effect or a triggered immune response. 1 Immune mediated hypersensitivity reactions are classified as B cell or T cell mediated. Type I, II and III reactions are B cell mediated. In type I reaction, an antigen binds to IgE on mast cells and basophils resulting in degranulation and release of inflammatory mediators. Type II reaction is a complement mediated reaction in which IgG or IgM bind to an antigen on the surface of the cells causing cell lysis. Type III reaction involves deposition of immune complex on different tissues causing vascuilitis and tissue damage. Type IV reaction is considered to be T cell mediated in which antigen binds covalently to a Major Histocompitability Complex (MHC) on the antigen presenting cells (APC) subsequently triggering a delayed hypersensitivity reaction. Another mechanism may involve antigen/T cell/MHC interaction through noncovalent binding. 1 Recent evidence suggests that most AED related hypersensitivity reactions are secondary to MHC dependent clonal T cell proliferation. 2 This has been documented with carbamazepine, valproic acid and lamotrigine induced hypersensitivity reactions.
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Although antiepileptic hypersensitivity reaction is commonly seen with therapy using older anticonvulsants, we report a case of a woman who developed angioedema related to levetiracetam monotherapy.
Case
A 33-year-old left handed woman had a generalized tonic clonic seizure at age 19 years and another at age 29 years. She then continued to have seizures once per month starting as a raising epigastric sensation, followed by loss of awareness, staring, lip smacking and bimanual automatisms progressing to a generalized tonic clonic seizure. She was a product of full term pregnancy with normal delivery. There was no history of febrile seizure, CNS infection or head trauma. Her neurological examination was unremarkable. EEG showed left temporal slowing. MRI revealed the presence of bilateral periventricular heterotopia.
Initial treatment with carbamazepine then valproic acid was not tolerated because of side effects. She was then maintained on phenytoin for several years but because of ongoing seizures topiramate was added. Since seizures remained unchanged, lamotrigine was slowly substituted for topiramate. When she reached 200 mg daily of lamotrigine a maculopapular skin rash developed and persisted until lamotrigine was discontinued. A return to phenytoin monotherapy then resulted in an intermittent skin rash occurring daily shortly after she took her medication. When she was admitted to the Epilepsy Monitoring Unit for Allergic reactions to antiepileptic drugs in the form of skin rash are not uncommon but angioedema, an acute life threatening reaction is rare. Angioedema has been reported with the use of oxcarbazepine and carbamazepine. We report a case of a 33-year-old woman with focal epilepsy who developed angioedema following levetiracetam monotherapy. The patient had previous skin rashes with both phenytoin and lamotrigine. Levetiracetam was stopped and she improved after treatment with norepinephrine, antihistamines and corticosteroids.
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investigation of possible surgical management phenytoin was discontinued and her rash disappeared. Seizures proved unlocalizable with scalp EEG during monitoring and she was placed on levetiracetam 500 mg daily as monotherapy. She was on no other medications and had been off phenytoin for one week. After the first dose of levetiracetam she developed a generalized maculopapular skin rash with associated swelling of the face, lips and tongue. Her blood pressure and O 2 saturation remained normal. CBC including eosinophils and immunology remained normal. Levetiracetam was discontinued and she was treated with IV norepinephrine, methylprednisone and antihistamines. The swelling of her lips and tongue resolved within 24 h and her skin rash disappeared in 3 days. Clobazam 30 mg daily was started which she tolerated well with no major side effects. She is to be readmitted for stereotaxic depth recording from her heterotopic tissue as well from the temporal lobes.
Discussion
Adverse drug reactions to AEDs in the form of skin rash have an incidence of 3-15%. 1, 3 The risk of developing such a reaction is higher with the use of aromatic AEDs such as phenobarbitol, phenytoin and carbamazepine. However lamotrigine, a nonaromatic AED, is also associated with a high frequency of skin rash especially if it is introduced rapidly. 4 The spectrum of allergic reaction varies from simple skin rash to more severe forms of Stevens-Johnson syndrome, toxic epidermal necrolysis or DRESS. 5 The latter, first described as a hypersensitivity reaction to AEDs, is characterized by rash, fever, pharyngitis, lymphadenopathy, eosinophilia and multiple organ dysfunction including hepatitis, nephritis, pneumonitis and encephalitis. With the exception of lamotrigine, newer AEDs such as levetiracetam have a much lower risk of developing allergic reactions than the older drugs. A recent case report of dose related drug eruption to levetiracetam has been described. 6 Angioedema is an allergic reaction similar in appearance to urticaria (hives) in which patients develop localized swelling in the dermis and submucosa. 7 It can be life threatening due to airway obstruction from laryngeal edema. Most commonly reported in patients taking angiotensin converting enzyme inhibitors or angiotensin receptor blockers, it occurs with a number of drugs. 8 Angioedema results from a Type I immune mediated hypersensitivity reaction when antigens to which the patient is sensitive bind to IgE on the surface of basophils and mast cells causing degranulation and release of inflammatory mediators. Although skin rashes are not uncommon with AEDs, the more serious reaction of angioedema is uncommon. Angioedema has been reported after oxcarbazepine 9 and carbamazepine administration. 10 This is the first report of angioedema from levetiracetam.
Cross-sensitivity to AEDs, as occurred in our patient, is more often encountered with aromatic AEDs such as phenytoin, phenobarbital, carbamazepine, oxcarbazepine and lamotrigine. There is a five times greater risk of allergic rash in patients with a past history of AED induced rash. 5 The rate of cross sensitivity to other aromatic AEDs may be as high as 71% between carbamazepine and oxcarbazepine. 11 Cross sensitivity between aromatic AEDs and lamotrigine is around 20%. 11 Although there are no reports of cross sensitivity between levetiracetam and other AEDs, this case appears to demonstrate cross sensitivity between phenytoin, lamotrigine and levetiracetam. Our patient developed an allergic rash to lamotrigine and subsequently had rash with phenytoin as well despite having taken the drug for several years before she became allergic to it. Late onset allergic reaction to a previously tolerated drug is a rare occurrence. Klassen reported a patient who tolerated phenytoin for 6 months before the introduction of carbamazepine. 12 The patient developed a hypersensitivity reaction which disappeared when both drugs were discontinued. However reintroduction of phenytoin resulted in diffuse skin rash after 2 doses. Gaig reported 5 cases of patients with anticonvulsant hypersensitivity reactions who developed an allergic reaction to other chemically unrelated drugs that were administrated during the episode of anticonvulsant hypersensitivity. 13 In our patient we think that lamotrigine induced an inflammatory immune response that subsequently lead to phenytoin and levetiracetam hypersensitivity. Although the newer antiepileptic drugs such as levetiracetam are generally considered to be safe to use in patients who have had an allergic reaction to aromatic AEDs, they still should be used with caution. In patients with prior AED hypersensitivity, the introduction of a new medication should be done slowly and with careful monitoring.
